Definition
Sipuleucel‑T is an autologous cellular immunotherapy approved for the treatment of asymptomatic or minimally symptomatic metastatic castration‑resistant prostate cancer (mCRPC). It is marketed under the trade name Provenge.
Overview
Sipuleucel‑T was the first therapeutic cancer vaccine to receive regulatory approval in the United States, receiving FDA clearance in April 2010. The therapy is produced from a patient's own peripheral blood mononuclear cells (PBMCs), which are harvested by leukapheresis, activated ex vivo with a recombinant fusion protein (PA2024) that links prostatic acid phosphatase (PAP), an antigen expressed by most prostate cancer cells, to granulocyte‑macrophage colony‑stimulating factor (GM‑CSF), an immune cell activator. After activation, the cells are reinfused into the patient as a series of three infusions administered approximately two weeks apart. Clinical trials demonstrated a median overall survival benefit of approximately four months compared with placebo, though progression‑free survival benefits were modest.
Etymology/Origin
The name “Sipuleucel‑T” is derived from components of its formulation and mechanism:
- “Si‑” references “specific immune,” reflecting its targeted immunologic action.
- “puleu” is derived from “prostatic urease‑like antigen,” an early descriptor for the target antigen (prostatic acid phosphatase).
- “‑cel” denotes “cellular,” indicating the therapy’s cellular basis.
- The suffix “‑T” stands for “therapy.”
The commercial name “Provenge” combines “PROstate” and “Vaccine.”
Characteristics
- Composition: Autologous PBMCs enriched for antigen‑presenting cells (mainly dendritic cells) activated with PA2024.
- Administration: Three intravenous infusions given at roughly two‑week intervals; each infusion is patient‑specific.
- Mechanism of Action: The activated antigen‑presenting cells process and present PAP to T cells, stimulating a cytotoxic immune response directed against PAP‑expressing prostate cancer cells.
- Indications: Approved for adult patients with asymptomatic or minimally symptomatic mCRPC who have not responded to hormonal therapy.
- Safety Profile: Common adverse events include infusion‑related reactions (fever, chills, headache, fatigue), hypertension, and neurotoxic effects such as transient confusion. Severe events are rare but may include cerebrovascular accidents.
- Regulatory Status: FDA‑approved (USA); also authorized in the European Union and Canada under conditional or compassionate‑use frameworks.
- Manufacturing: Requires a centralized processing facility; the entire process from leukapheresis to reinfusion typically takes 2–3 days per batch.
Related Topics
- Prostate Cancer – disease for which Sipuleucel‑T is indicated.
- Cancer Immunotherapy – broader field encompassing checkpoint inhibitors, CAR‑T cells, and therapeutic vaccines.
- Dendritic‑Cell Vaccines – class of immunotherapies that use patient‑derived antigen‑presenting cells.
- Prostatic Acid Phosphatase (PAP) – target antigen of Sipuleucel‑T.
- Granulocyte‑Macrophage Colony‑Stimulating Factor (GM‑CSF) – cytokine used in the activation of the cellular product.
- Leukapheresis – procedure for collecting PBMCs from patients.
- Provenge (Trade Name) – commercial branding of Sipuleucel‑T.